IL17A and rheumatoid arthritis: Although IL-17 is a potentially attractive therapeutic target in RA, randomised phase 2 placebo controlled trials of IL-17 inhibitors in RA have yielded disappointing results such that these agents are not currently used in the treatment of RA [90, 91].